Bellerophon Provides Clinical Program Update and Reports : c

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 ...

Related Keywords

New Jersey , United States , Peter Fernandes , Baylor Biosciences , Brian Ritchie , Baylor Bioscience , Exchange Commission , Jersey Technology Business Tax Certificate Transfer Program , Clinical Program , Nasdaq , Baylor Biosciences Inc , Bellerophon Therapeutics Inc , Last Patient Completed Blinded Treatment , Pivotal Top Line Data Expected , Chief Executive , Program Highlights , Interstitial Lung Disease , Vigorous Physical Activity , Quarter Ended March , Financial Results , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , Operations And Comprehensive Income , Nasdaq Blph , Bellerophon Therapeutics , Nc ,